5 recruiting, 2 completed, 2 terminated, 1 unknown. 10 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 5, Completed 2, Terminated 2, Unknown 1 |
| Phase 1 | 7 | Recruiting 4, Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Solid Carcinoma: new trials by email Literature Review of Solid Carcinoma trials Research Report on Solid Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DM002 in Patients With Advanced Solid Tumors DM002 - Ovarian Neoplasms, Prostatic Neoplasms | Phase 1 / Phase 2 | Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | 280 | 2025-02-17 | 2026-08-07 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| A Study of DM005 in Patients With Advanced Solid Tumors DM005 - Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 / Phase 2 | Recruiting | Doma Biopharmaceutical（Suzhou）Co., Ltd. | 208 | 2024-10-31 | 2026-08-07 |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies S241656, FOLFOX6/FOLFOX7, FOLFIRI - Non-small Cell Lung Cancer, Histiocytic Neoplasm | Phase 1 / Phase 2 | Recruiting | Institut de Recherches Internationales Servier | 554 | 2023-04-18 | 2026-10-13 |
| PRE-ISPY Phase I/II Oncology Platform Program ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab - HER2-positive Breast Cancer, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 280 | 2023-02-15 | 2026-09-30 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Mirdametinib, Fulvestrant - Breast Cancer, Breast Cancer Stage IV | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 6 | 2021-09-14 | 2025-05-23 |
| A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors Romiplostim - Solid Tumor, Solid Tumor, Childhood | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 2 | 2020-12-10 | 2025-05-28 |
| Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Benralizumab - Solid Tumor, Solid Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 51 | 2020-09-16 | 2026-06-01 |
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
Colorectal Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Prostatic Neoplasms (2) · Stomach Neoplasms (2) · Thyroid Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Anus Neoplasms (1) · Brain Neoplasms (1)
Neoplasms by Site (9) · Neoplasms (7) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Intestinal Diseases (5) · Intestinal Neoplasms (5) · Lung Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Rectal Diseases (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5)
130-nm albumin-bound paclitaxel (1) · ALX148 (1) · Cetuximab (1) · Fluorouracil (1) · Fulvestrant (1) · Gemcitabine (1) · IFL protocol (1) · Leucovorin (1) · Panitumumab (1) · benralizumab (1) · mirdametinib (1) · niraparib (1) · romiplostim (1) · tucatinib (1) · zanidatamab (1)
Memorial Sloan Kettering Cancer Center (3) · Aminex Therapeutics, Inc. (1) · Doma Biopharmaceutical（Suzhou）Co., Ltd. (1) · Institut de Recherches Internationales Servier (1) · QuantumLeap Healthcare Collaborative (1) · RenJi Hospital (1) · Tarveda Therapeutics (1) · Xadcera Biopharmaceutical (Suzhou) Co., Ltd. (1)
United States (9) · Australia (4) · China (2) · Denmark (1) · France (1) · Hong Kong (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Alina Markova, MD (1) · Anish Thomas, MD (1) · Ezra Rosen, MD, PhD (1) · Jianjun Liu, Ph.D. & M.D. (1) · Michael Armstrong, MD (1) · Michael Ortiz, MD (1) · Paula R Pohlmann, MD, MSc, PhD (1) · Sue Lee, MD (1) · Weijun Wei, Ph.D. & M.D. (1)
2025 (1)